Progestins initiate adverse events of menopausal estrogen therapy

Climacteric

Volumn 6, Issue 4, 2003, Pages 293-301

  Thomas, T ^a,b   Rhodin, J ^a   Clark, L ^a   Garces, A ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Woodlands Med and Research Center   (United States)

Author keywords

Cardiovascular disease; Dementia; Estrogen; Hormone replacement therapy; Menopause; Progesterone; Progestin; Stroke; Thromboembolism

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; PROGESTERONE; PROGESTERONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; BIOACCUMULATION; BLOOD CELL; BLOOD CLOTTING; BLOOD FLOWMETRY; BLOOD VESSEL; CELL ULTRASTRUCTURE; CONTROLLED STUDY; ENDOTHELIUM INJURY; ESTROGEN THERAPY; FEMALE; FLUORESCENCE; INFLAMMATION; MENOPAUSAL SYNDROME; MICROSCOPY; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE ACTIVATION; THROMBOGENESIS; VASCULAR DISEASE; VIDEORECORDING;

EID: 1642578950     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/cmt.6.4.293.301     Document Type: Article

References (37)

1. Barnes RB, Levrant SG. Pharmacology of estrogens. In Lobo RA, ed. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. Philadelphia, PA: Lippincott Williams and Wilkins, 1999:95-104
2. Thomas T. A role for estrogen in the primary prevention of Alzheimer's disease. Climacteric 2001;4:102-9
3. Keating NL, Cleary PD, Rossi AS, et al. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999;130:545-53
4. Stampfer MJ, Colditz GA. Estrogen replacement and coronary heart disease: a quantitative assessment of epidemiologic evidence. Prev Med 1991;20:47-63
5. Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer's disease in older women: the Cache County Study. J Am Med Assoc 2002;288:2123-9
6. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. J Am Med Assoc 1998;279:688-95
7. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998;280:605-13
8. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on progression of coronary artery atherosclerosis. N Engl J Med 2000;343:522-9
9. Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-9
10. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-53
11. Henderson VW, Paganini-Hill A, Miller BI, et al. Estrogen for Alzheimer disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000;54:295-301
12. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. J Am Med Assoc 2000;283:1007-15
13. Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology 2000;54:2061-6
14. Heijer TD, Greelings MI, Hofman A, et al. Higher estrogen levels are not associated with larger hippocampi and better memory performance. Arch Neurol 2003;60:213-20
15. Thal LJ, Thomas RG, Mulnard R, et al. Estrogen levels do not correlate with improvement in cognition. Arch Neurol 2003;60:209-12
16. Writing Group for Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized control trial. J Am Med Assoc 2002;288:321-33
17. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. J Am Med Assoc 2003;289:2651-62
18. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. J Am Med Assoc 2003;289:2663-72
19. Yaffe K. Hormone therapy and the brain. Déjà vu all over again? J Am Med Assoc 2003;289:2717-19
20. Wassertheil-Smoller S. Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. J Am Med Assoc 2003;289:2673-84
21. Rhodin J, Thomas T. A vascular connection to Alzheimer's disease. Microcirculation 2001;8:207-20
22. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part 1: Aging arteries: a 'set up' for vascular disease. Circulation 2003;107:139-46
23. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease - prospective analysis from the Women's Health Initiative observational study. J Am Med Assoc 2002;288:980-7
24. Thomas T, Rhodin J, Bryant M, et al. Estrogen and raloxifene activities on amyloid-β induced inflammatory reaction. Microvasc Res 2001;61:28-39
25. Thomas T, Rhodin J, Sutton ET, Bryant M, Price J. Estrogen protects peripheral and cerebral blood vessels from amyloid-β toxicity and inflammatory reaction. J Submicrosc Cytol Pathol 1999;31:571-9
26. Rhodin JA, Thomas T, Clark L, Garces A. In vivo cerebrovascular actions of amyloid β-peptides and the protective effect of conjugated estrogens. J Alzheimer's Dis 2003;5:275-86
27. Lefer DJ, Granger ND. Monocyte rolling in early atherogenesis - vital role in lesion development. Circ Res 1999;84:1353-5
28. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-21
29. Becattini C, Agnelli G. Pathogenesis of venous thromboembolism. Curr Opin Pulm Med 2002;8:360-4
30. Rodriguez-Manzaneque JC, Graubert M, Iruela-Arispe ML. Endothelial cell dysfunction following prolonged activation of progesterone receptor. Hum Reprod 2000;(Suppl 3):39-47
31. Badimon L, Bayes-Genis A. Effects of progestogens on thrombosis and atherosclerosis. Hum Reprod Update 1999;5:191-9
32. Aisen PS, Schafer KA, Grundman M. et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression. J Am Med Assoc 2003;289:2819-26
33. Sutton ET, Thomas T, Bryant MW, et al. Amyloid-β peptide induced inflammatory reaction is mediated by the cytokines tumor necrosis factor and interleuken-1. J Submicrosc Cytol Pathol 1999;31:313-23
34. Nilsen J, Brinton RD. Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc Natl Acad Sci USA 2003;100:10506-11
35. Branger J, van den Blink B, Weijer S, et al. Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen activated protein kinase inhibitor during human endotoxemia. Blood 2003;101:4446-8
36. Register TC, Adams MR, Golden DL, Clarkson TB. Conjugated estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol 1998;18:1164-71
37. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nature Med 1997;3:324-7